Off-Label HIV Regimen Data Should Be Provided To Doctors By FDA - Cmte.
FDA should educate doctors about new HIV regimens to correct potentially misleading information in off-label reprints, members of FDA's Antiviral Drugs Advisory Committee suggested July 25.
You may also be interested in...
FDA's ability to introduce sponsor dissemination of off-label reprints as evidence in enforcement action litigation may be the next item open for constitutional questioning, following the Feb. 11 dismissal of Washington Legal Foundation v. Henney by the Washington D.C. appeals court.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials